---
canonical_name: Muira Puama
alternate_names: Ptychopetalum olacoides, Ptychopetalum uncinatum, Marapuama, Muirapuama, Potency Wood, Liriosma ovata
canonical_topic: Muira Puama for Health & Longevity
short_topic_lc: muira_puama
creation_date: 2026-0825-0159
creator_ai_fullname: Opus 5
ep_keywords: Herbal Aphrodisiacs, Adaptogens
---

# Muira Puama for Health & Longevity
<section id="top" markdown="1"></section>  
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Ptychopetalum olacoides, Ptychopetalum uncinatum, Marapuama, Muirapuama, Potency Wood, Liriosma ovata

  
## Motivation

<!-- This motivation section was written last, after every other section of this review was complete, so that it reflects the full scope of what the evidence actually supports rather than what the topic promises. -->

Muira puama is the root and bark of a small Amazonian tree, *Ptychopetalum olacoides*, sold for generations under the nickname "potency wood." It is a common plant name rather than a botanical name, and it reaches Western shelves mostly as capsules and alcohol-based tinctures aimed at sexual desire, energy and mental sharpness. What makes it unusual is that its traditional reputation runs in two directions at once: a sexual tonic and a remedy for nervous exhaustion.

Amazonian communities prepared root infusions for weakness, nervous complaints and loss of sexual function long before the plant entered European herbal practice in the nineteenth century. Laboratory work in Brazil later pushed it toward the brain, while a separate line of work in the United States has tested it inside multi-ingredient formulas aimed at ageing blood vessels. Human testing of the herb on its own has stayed thin throughout.

This review examines what is genuinely established about muira puama: what its active parts do, what the human and animal studies actually show, where the evidence is thin or missing, what the safety and product-quality picture looks like, and how it is typically dosed and tracked.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

High-level sources that discuss muira puama, or the herbal category it belongs to, in enough depth to orient a reader before the detailed evidence.

<!-- Search performed 20 August 2026. I ran web searches for "muira puama" combined with each priority expert name, and on-site searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com and lifespan.io using each site's own search function. Only lifeextension.com returned dedicated coverage. I additionally searched PubMed and the open web for narrative reviews and primary sources that treat the herb, rather than merely list it. -->

* [Replenish Testosterone Naturally](https://www.lifeextension.com/magazine/2000/1/cover2) - Life Extension

  Devotes a full section to muira puama, summarizing both of Jacques Waynberg's uncontrolled clinical studies in men. Life Extension sells muira puama-containing products, a direct commercial interest in these conclusions.

* [Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects](https://pubmed.ncbi.nlm.nih.gov/33066617/) - Brunetti et al., 2020

  Narrative review covering fifteen herbal aphrodisiacs including *Ptychopetalum olacoides*; the most complete published account of what is and is not known about muira puama's neurological and psychiatric safety.

* [Brazilian plants as possible adaptogens: an ethnopharmacological survey of books edited in Brazil](https://pubmed.ncbi.nlm.nih.gov/17030478/) - Mendes & Carlini, 2007

  Places muira puama among only four Brazilian species with both widespread traditional adaptogen use and supporting pharmacology, giving useful context for the anti-fatigue and anti-stress claims.

* [Ethnobotanical treatment strategies against Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/22329652/) - Howes & Houghton, 2012

  Reviews plants with relevance to dementia and discusses *Ptychopetalum olacoides* alongside better-studied species, framing cognitive claims against wider evidence for plant acetylcholinesterase inhibitors (blockers of the enzyme that breaks down the memory chemical acetylcholine).

Only four items qualify. Direct searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com and lifespan.io returned no muira puama content, so Life Extension is the only priority source represented, and the remaining eligible material is product marketing, database entries, or passing mentions that do not meet the depth bar. The list has deliberately not been padded.

  
## Grokipedia

<!-- grokipedia.com searched directly with the browser tool on 20 August 2026 for "Muira puama". Five results returned; the primary dedicated page for the plant is filed under its botanical genus, Ptychopetalum. -->

[Ptychopetalum](https://grokipedia.com/page/Ptychopetalum)

Covers the genus botanically and commercially: taxonomy, Amazonian distribution, traditional uses, constituent chemistry, harvesting pressure, and the herb's unregulated status as a dietary supplement in the United States.

  
## Examine

<!-- examine.com searched directly with the browser tool on 20 August 2026 for "muira puama". The site search returned one intervention page, which is the dedicated supplement entry for the herb. -->

[Muira puama](https://examine.com/supplements/muira-puama/)

Summarizes muira puama as an aphrodisiac and nerve tonic with weak human sexuality evidence, and gives the extract dose range most commonly used, converted from rodent anti-stress work.

  
## ConsumerLab

<!-- consumerlab.com searched directly with the browser tool on 20 August 2026 for "muira puama". The search returned a members-only sexual-enhancer product review, several FDA warning-letter summaries, and one unrelated answer page. No dedicated muira puama review, product report or ingredient page exists. -->

ConsumerLab has published no dedicated muira puama review, product report or ingredient page. The herb surfaces only inside a members-only Sexual Enhancer Supplements Review, which tests yohimbe, horny goat weed and arginine products rather than muira puama itself, and inside archived summaries of regulatory warning letters.

  
## Systematic Reviews

<!-- PubMed searched 20 August 2026 with "(Ptychopetalum OR "muira puama" OR muirapuama) AND (systematic review OR meta-analysis)", returning zero records, and with the intervention terms alone, returning fifty records, none of which is a systematic review or meta-analysis. Broader searches of herbal sexual-function reviews were also run; those reviews cover the category, not this herb. -->

No systematic reviews or meta-analyses for Muira puama were found on PubMed as of August 20, 2026.

Neither side of the trade-off is represented: there is no systematic review or meta-analysis of the claimed benefit (sexual function) and none of the principal risk (central nervous system overstimulation and product adulteration). [Category-level reviews of herbal erectile-dysfunction supplements](https://pubmed.ncbi.nlm.nih.gov/29633089/) exist but found no eligible muira puama trial to include.

  
## Mechanism of Action

Muira puama is a whole-plant extract, not a single molecule, and its activity is spread across several [constituent classes](https://pubmed.ncbi.nlm.nih.gov/28750557/): free long-chain fatty acids and plant sterols, the alkaloids magnoflorine and menisperine, clerodane diterpenes, and flavonoids such as luteolin.

Three mechanisms have laboratory support. First, ethanol extracts [inhibit acetylcholinesterase](https://pubmed.ncbi.nlm.nih.gov/12895682/) in the frontal cortex, hippocampus and striatum — the same target as approved dementia drugs. Second, several [clerodane diterpenes potentiate nerve growth factor](https://pubmed.ncbi.nlm.nih.gov/18821798/) (NGF, a protein that keeps neurons alive and connected), and the extract raises [brain catalase and glutathione peroxidase activity](https://pubmed.ncbi.nlm.nih.gov/17433649/), two antioxidant enzymes. Third, in penile and vascular smooth muscle — tested only inside a four-ingredient formula, COMP-4, developed and sold as Revactin by the same group that publishes this line of work, a direct commercial interest — it [upregulates nitric oxide synthase](https://pubmed.ncbi.nlm.nih.gov/34430391/), the enzyme family that makes nitric oxide, raising nitric oxide and its downstream messenger cyclic GMP (a signalling molecule that relaxes smooth muscle). That is the relaxation pathway erectile drugs prolong.

Antidepressant-like rodent effects were [blocked by beta-adrenergic and D1 dopamine receptor antagonists](https://pubmed.ncbi.nlm.nih.gov/19067380/) (drugs that block adrenaline and dopamine signalling), implying that adrenaline- and dopamine-type messengers rather than serotonin are involved.

A competing explanation deserves equal weight: in the vascular and human work the herb is never given alone, so ginger, guarana and L-Citrulline may account for the nitric oxide effects. No human pharmacokinetic study exists, so half-life, tissue distribution, metabolising enzymes and selectivity are all uncharacterised.

  
## Historical Context & Evolution

Muira puama entered the written record as a general Amazonian remedy, not a sexual product. Tupi-speaking communities in the Brazilian and Guyanese lowlands prepared root and bark infusions for neuromuscular weakness, rheumatism, digestive complaints, nervous exhaustion and impotence, and the name translates roughly as "potency wood." European pharmacy adopted it in the nineteenth century, listing it as a tonic and astringent.

Chemistry came slowly. German investigators in the late 1960s and early 1970s [isolated its lipophilic constituents](https://pubmed.ncbi.nlm.nih.gov/5291273/) and established that the actives are fat-soluble — which is why water decoctions extract poorly and why commercial products are alcohol-based.

The modern sexual-health reputation rests on two open, uncontrolled clinical series run in Paris in the early 1990s by Jacques Waynberg, [described in a supplement retailer's magazine](https://www.lifeextension.com/magazine/2000/1/cover2) as reporting gains in libido, erection stability and fatigue within two weeks. Those series were never placebo-controlled and were not published in indexed journals. That is a limitation rather than a refutation: no controlled trial has tested the claim and failed it either, because none has been run.

A separate Brazilian programme from the late 1990s moved the herb toward neurology, documenting [acetylcholinesterase inhibition](https://pubmed.ncbi.nlm.nih.gov/12895682/) and anti-amnesic effects in rodents. Since 2015 a United States group has studied it inside [nitric-oxide-stimulating combinations](https://pubmed.ncbi.nlm.nih.gov/26405615/) for vascular and bone outcomes.

  
## Expected Benefits

<!-- Before writing this section I searched PubMed for all fifty indexed records on Ptychopetalum olacoides, muira puama and muirapuama, searched ClinicalTrials.gov for registered trials of the herb and its branded combinations, and cross-checked the resulting benefit list against Examine.com's supplement entry, the Grokipedia genus page and drug-reference summaries, to confirm that no claimed benefit category was omitted. -->

### High 🟩 🟩 🟩

No benefit reaches this level. No meta-analysis exists, and no placebo-controlled trial of muira puama on its own has ever been published.

### Medium 🟩 🟩

No benefit reaches this level either. Every positive human result comes either from uncontrolled studies or from multi-ingredient formulas in which the herb cannot be isolated.

### Low 🟩

#### Increased Sexual Desire and Erectile Function

The best-known claim. Two uncontrolled clinical series in men and one [open study in women taking a muira puama and *Ginkgo biloba* combination](https://pubmed.ncbi.nlm.nih.gov/11186145/) reported higher desire, erection stability and satisfaction within two to four weeks. No placebo-controlled trial of the herb alone exists, and the systematic review base contains none.

**Magnitude:** In the open study of 202 women, 65% recorded higher total sexual-function scores after one month; Waynberg's uncontrolled series in 262 men reported 62% rating libido improved and 52% rating erection improved after two weeks, [as summarized in a supplement retailer's magazine](https://www.lifeextension.com/magazine/2000/1/cover2). A separate [three-month pilot of a four-ingredient formula in 54 men](https://pubmed.ncbi.nlm.nih.gov/29732286/) found erectile-function scores rising from a median (the middle value of the group) of 16 at baseline to 21, 22 and 19 at one, two and three months.

#### Reduced Symptoms of Burning Mouth Syndrome

A [randomized, double-blind, placebo-controlled trial of Catuama](https://pubmed.ncbi.nlm.nih.gov/22669143/) — a Brazilian four-herb formula containing muira puama, guarana, catuaba and ginger — reduced the oral burning of burning mouth syndrome (unexplained chronic mouth pain). Attribution to muira puama specifically is untested, since the ingredients were never separated.

**Magnitude:** In 72 patients, symptom scores fell further with the formula than with placebo at four weeks on the faces scale alone (p = 0.010, where p is the probability the difference arose by chance, so smaller means less likely), at eight weeks on both rating scales (p = 0.03 and p < 0.001) and at twelve weeks on both (p = 0.001); the report gives no between-group score difference or effect size (a standardised measure of how large the difference is).

#### Improved Artery Dilation and Lower Clotting-Marker Levels

Muira puama is one of four ingredients in COMP-4, which raises nitric oxide output in [human vascular cells](https://pubmed.ncbi.nlm.nih.gov/39913351/). A completed 32-person open-label trial reported improved artery dilation and lower plasminogen activator inhibitor-1 (a clotting-brake protein that rises with age); those results are registry-stated and still unpublished.

**Magnitude:** The follow-up trial registration reports direction only — dilation rose and plasminogen activator inhibitor-1 fell over fourteen days of twice-daily dosing — and gives no figures; the literature reports no outcome figure because the primary manuscript remains under review.

### Speculative 🟨

#### Reduced Fatigue and Improved Stress Resilience ⚠️ Conflicted

[Rodent work](https://pubmed.ncbi.nlm.nih.gov/19682881/) shows the extract blocks stress-induced anxiety and high blood sugar, though [an earlier rodent study](https://pubmed.ncbi.nlm.nih.gov/12164265/) instead found anxiety-like effects. Human evidence is limited to uncontrolled reports of reduced fatigue.

#### Memory Retention and Neuroprotection

In mice the extract [improves memory retrieval](https://pubmed.ncbi.nlm.nih.gov/15507336/) and [limits amyloid-driven damage](https://pubmed.ncbi.nlm.nih.gov/20739160/), matching its acetylcholinesterase inhibition. No human cognitive trial has been run, so this remains animal-level evidence only.

#### Elevated Mood

The extract [reduces immobility in rodent despair models](https://pubmed.ncbi.nlm.nih.gov/19067380/), an effect blocked by beta-adrenergic and dopamine blockers, and [reverses grooming loss and stress-hormone rises](https://pubmed.ncbi.nlm.nih.gov/18513902/) in a chronic mild stress model. No human depression study exists.

#### Preserved Bone Mineral Density

In [rats with ovaries removed](https://pubmed.ncbi.nlm.nih.gov/31275540/), a four-ingredient formula containing muira puama restored bone density and turnover markers toward normal, comparably to estradiol. Animal data only; no human bone study has been attempted.

#### Relieved Joint and Muscle Pain

One of the oldest traditional uses. The basis is mechanistic only: the extract [scavenged free radicals in a screen of Amazonian anti-inflammatory plants](https://pubmed.ncbi.nlm.nih.gov/26921197/). No animal pain model or human trial exists.

  
## Benefit-Modifying Factors

* **Underlying cause of sexual complaint:** Waynberg reported his largest gains, [per a supplement retailer's magazine](https://www.lifeextension.com/magazine/2000/1/cover2), in men whose difficulty carried the least psychological component; established vascular disease, diabetic nerve damage or fibrosis of erectile tissue leaves far less room for a mild nitric-oxide effect.

* **Baseline sexual-function score:** People starting from a mid-range score have the most measurable headroom. Those already scoring near the ceiling of a standard erectile-function questionnaire should expect little detectable change, since the reported effects are modest.

* **Baseline oxidative and vascular markers:** The rodent antioxidant and human nitric-oxide findings both target a degraded baseline. Higher baseline inflammation, poorer artery flexibility and older vascular age plausibly leave more to recover, though no trial has stratified participants this way.

* **Sex:** Human data in women come from [a single open study of a muira puama and *Ginkgo biloba* combination](https://pubmed.ncbi.nlm.nih.gov/11186145/) reporting gains in desire, arousal and orgasm. No dose, formulation or response difference between sexes has been established.

* **Genetic variation:** No pharmacogenetic data exist for this herb. Variants in BCHE (the gene for butyrylcholinesterase, a back-up enzyme that clears acetylcholine) or APOE4 (a variant raising Alzheimer's risk) are plausible modifiers of the cholinergic effects but entirely untested.

* **Pre-existing health conditions:** Untreated low testosterone, thyroid disease, depression and sleep apnoea all suppress desire through routes the herb does not touch. Where one of these dominates, correcting it will outweigh any herbal effect.

* **Age:** Rodent benefits were largest in aged animals, and [the human vascular trial](https://clinicaltrials.gov/study/NCT05595915) recruited people aged 18 to 39, so nothing is known about the response at the older end of the target range where the mechanism should matter most.

  
## Potential Risks & Side Effects

<!-- Before writing this section I cross-checked drug-reference summaries (drugs.com natural products monographs, RxList) and the Brunetti 2020 review of psychiatric and neurological adverse effects of herbal sexual enhancers against PubMed searches for Ptychopetalum toxicity, adverse events and adulteration, plus ConsumerLab's regulatory warning summaries, to confirm no known adverse-effect category is missing. -->

### High 🟥 🟥 🟥

#### Undisclosed Pharmaceutical Adulterants in Marketed Products

The dominant real-world hazard is not the plant but what is hidden alongside it. Sexual-enhancement supplements are the single largest category of products carrying [United States Food and Drug Administration adulteration warnings](https://pubmed.ncbi.nlm.nih.gov/30646238/), most often for concealed erectile-dysfunction drugs and their unapproved chemical analogues, and muira puama is a staple ingredient of exactly this product class. Concealed phosphodiesterase-5 inhibitors — the drug class that includes sildenafil — can cause severe blood-pressure collapse in anyone taking nitrate heart medication, who has no way of knowing they are exposed.

**Magnitude:** Of 776 adulterated supplements flagged by the Food and Drug Administration between 2007 and 2016, 353 (45.5%) were marketed for sexual enhancement, and sildenafil was detected in 47.0% of those; 67.9% of products warned about more than once were found to contain a new hidden drug the second time.

### Medium 🟥 🟥

#### Gastrointestinal Upset and Headache

Mild digestive complaints and headache are the side effects actually recorded in human use. In a [three-month pilot of a four-ingredient formula](https://pubmed.ncbi.nlm.nih.gov/29732286/), five of fifty-four men reported indigestion, heartburn or migraine, none rated severe. A [28-day tolerability study of the four-herb formula Catuama](https://pubmed.ncbi.nlm.nih.gov/15798997/) found no serious adverse reactions and no blood-count or blood-chemistry changes. Both used combinations, so herb-specific attribution is uncertain, and neither was placebo-controlled.

**Magnitude:** Five of 54 men (9.3%) reported a treatment side effect over three months, none severe; the separate 28-day study reported no laboratory abnormality in either sex.

### Low 🟥

#### Central Nervous System Overstimulation ⚠️ Conflicted

Restlessness, agitation and disturbed sleep are the standard cautions at higher intakes, consistent with the herb's stimulant reputation. The rodent evidence is conflicted: one study found the extract [reduced exploratory behaviour in a pattern read as anxiety-provoking](https://pubmed.ncbi.nlm.nih.gov/12164265/), while another found it [prevented stress-induced anxiety](https://pubmed.ncbi.nlm.nih.gov/19682881/) without being calming on its own.

**Magnitude:** Not quantified in available studies. No controlled human trial has recorded sleep or anxiety outcomes for muira puama, so the caution rests entirely on rodent behavioural work and uncontrolled use reports.

### Speculative 🟨

#### Additive Cholinergic Effects

Because the extract inhibits acetylcholinesterase, combining it with prescription dementia drugs or other cholinesterase-inhibiting botanicals could in principle produce nausea, cramping, slow heart rate or excess salivation. No such case has been published.

#### Estrogen-Receptor Activity

A [computer-docking screen](https://pubmed.ncbi.nlm.nih.gov/25878948/) predicted that eight muira puama constituents bind the estrogen receptor. This is a modelling result only, with no cell, animal or human confirmation and no reported hormonal effect in users.

  
## Risk-Modifying Factors

* **Baseline anxiety and insomnia:** An existing anxiety disorder or fragile sleep is the clearest amplifier, since the only replicated behavioural signal in animals is stimulation rather than sedation. Evening dosing compounds this.

* **Baseline biomarkers:** Liver enzymes above the functional range, or a resting blood pressure already below 110/70 mmHg, narrow the safety margin, since clearance is uncharacterised and the nitric-oxide pathway adds further vasodilation.

* **Nitrate use and cardiovascular disease:** The adulteration hazard becomes lethal rather than merely serious in anyone on nitroglycerin or long-acting nitrates, because a hidden erectile-dysfunction drug plus a nitrate can collapse blood pressure.

* **Hormone-sensitive conditions:** Breast, uterine and prostate cancers, endometriosis and uterine fibroids are theoretical concerns given the predicted estrogen-receptor binding of several constituents, although no measured hormonal effect has ever been demonstrated.

* **Genetic variation:** No enzyme-level metabolism data exist for this extract, so variants in CYP3A4 (the liver enzyme that handles most drugs) or BCHE cannot be assessed. This is an unknown, not a cleared risk.

* **Liver and kidney impairment:** Because clearance is uncharacterised and products are frequently alcohol-based tinctures, reduced liver or kidney function shifts an already unquantified exposure further into the unknown.

* **Sex:** Adverse-event data in women come from [one open combination study](https://pubmed.ncbi.nlm.nih.gov/11186145/) reporting good tolerability. Nothing establishes whether the stimulant or hormonal concerns differ by sex.

* **Age:** Older users take more medications overall, hold more nitrate prescriptions and carry more sensitivity to cholinergic and blood-pressure effects, so the same dose carries a wider interaction surface at the older end of the target range.

  
## Key Interactions & Contraindications

* **Nitrates (nitroglycerin, isosorbide dinitrate, amyl nitrite):** Absolute contraindication with any unverified sexual-enhancement product, because concealed erectile-dysfunction drugs plus nitrates cause a profound drop in blood pressure and cardiovascular collapse. Mitigation: single-ingredient, third-party-tested products only.

* **Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil):** Caution. Shared nitric-oxide pathway means additive vasodilation, with headache, flushing and low blood pressure. Mitigation: an unchanged prescription dose, with the herb added only under blood-pressure monitoring.

* **Cholinesterase inhibitors (donepezil, rivastigmine, galantamine):** Caution. Additive blockade of acetylcholine breakdown can cause nausea, cramping, slow heart rate and excess salivation. Mitigation: avoidance of the combination, or a halved herbal dose with pulse monitoring.

* **Anticholinergic drugs (oxybutynin, benztropine, sedating antihistamines):** Monitor. These block acetylcholine signalling, the opposite of the herb's effect, so each may blunt the other. Mitigation: dosing separated by four hours, with reassessment of whether either is working.

* **Antihypertensives (amlodipine, lisinopril, doxazosin):** Caution. Additive blood-pressure lowering through the nitric-oxide pathway, with dizziness on standing. Mitigation: seated and standing blood-pressure readings two weeks after starting.

* **Monoamine oxidase inhibitors (phenelzine, tranylcypromine):** Caution. These older antidepressants raise noradrenaline and dopamine, the same messengers behind the antidepressant-like rodent effect. Mitigation: avoidance of the combination, given the theoretical risk of hypertensive or agitated reactions.

* **Over-the-counter stimulants and alcohol:** Monitor. Caffeine tablets and energy products stack with the herb's stimulant profile to worsen insomnia and restlessness; alcohol-based tinctures add ethanol. Mitigation: a capped total caffeine intake and capsules in preference to tinctures.

* **Nitric-oxide-boosting supplements (L-Citrulline, L-Arginine, beetroot nitrate, Pycnogenol):** Caution. Additive by design, since these are the co-ingredients in the studied formulas; consequence is additive vasodilation and low blood pressure. Mitigation: one addition at a time.

* **Cholinesterase-inhibiting botanicals (huperzine A, *Bacopa monnieri*, galantamine-containing extracts):** Caution. Additive cholinergic load, with the same nausea and slow-heart-rate consequences as the prescription class. Mitigation: no stacking; a single acetylcholine-sparing agent at a time.

* **Yohimbine and *Panax ginseng*:** Caution. Both add sympathetic stimulation and pro-erectile effect, raising the chance of anxiety, palpitations and raised blood pressure. Mitigation: no combining of stimulant aphrodisiacs; yohimbine in particular has a narrow margin.

* **Other interventions (testosterone therapy, low-intensity shockwave therapy):** Monitor. A [rat pelvic-injury model](https://pubmed.ncbi.nlm.nih.gov/39845379/) found additive recovery of sexual function when shockwave treatment was combined with a muira puama formula; consequence in people is unknown. Mitigation: one treatment added at a time.

**Populations who should avoid Muira puama:**

* Pregnancy and lactation — no reproductive toxicology of any kind exists for this extract.
* Anyone under 18 years of age — no paediatric safety or dosing data.
* Anyone taking nitrates for angina, or within 90 days of a myocardial infarction (heart attack), because of the adulteration hazard.
* New York Heart Association Class III–IV heart failure (marked limitation of activity, or symptoms at rest) — additive vasodilation is poorly tolerated.
* Child-Pugh Class B or C liver impairment (moderate to severe liver failure) — clearance is entirely uncharacterised.
* Active or prior hormone-sensitive cancer (breast, uterine, prostate) — precautionary, given predicted estrogen-receptor binding.
* Uncontrolled anxiety disorder or chronic insomnia — the only replicated behavioural signal is stimulation.
* Known hypersensitivity to muira puama or other Olacaceae family plants.

  
## Risk Mitigation Strategies

* **Single-ingredient, third-party-tested product:** A plain muira puama extract carrying an independent testing mark, rather than a proprietary "male enhancement" blend, removes the largest documented hazard — hidden erectile-dysfunction drugs in multi-ingredient sexual supplements.

* **Medication-list screen for nitrates before starting:** Confirmation that no nitrate, nicorandil or amyl nitrite is in use prevents the one interaction that turns a hidden adulterant from a serious problem into a fatal blood-pressure collapse.

* **Start dose of 500 mg daily with titration over two weeks:** Roughly a third of the usual 1,000–1,500 mg extract dose, stepped up weekly, exposes stimulation, restlessness or digestive upset at a dose low enough to reverse.

* **Full daily dose taken before 14:00:** Morning or early-afternoon dosing keeps the stimulant profile away from sleep onset, the most commonly reported complaint at higher intakes.

* **No stacking of acetylcholine-sparing agents:** Avoidance of simultaneous huperzine A, *Bacopa monnieri* or prescription dementia drugs prevents additive cholinergic effects — nausea, cramping, slow heart rate — that no study has quantified for this combination.

* **Blood-pressure check at two weeks:** A seated and standing reading two weeks after starting catches additive vasodilation from the nitric-oxide pathway before dizziness or falls occur, particularly in anyone on blood-pressure medication.

* **Trial capped at 8–12 weeks with reassessment:** A fixed stop point prevents indefinite exposure to a compound with no long-term human safety data, and forces an honest judgement about whether anything actually changed.

* **Two-week pause before elective surgery:** Stopping ahead of anaesthesia avoids unpredictable interaction between the herb's cholinergic activity and neuromuscular blocking agents (the muscle-relaxing drugs used during general anaesthesia), which is untested rather than known to be safe.

  
## Therapeutic Protocol

* **Standard extract dose:** 1,000–1,500 mg daily of a 4:1 concentrated extract, equivalent to roughly 4–6 g of crude root and bark. This is the [range Examine.com derives](https://examine.com/supplements/muira-puama/) from both clinical and rodent dosing.

* **Original clinical schedule:** Waynberg's Paris series, [per a supplement retailer's magazine](https://www.lifeextension.com/magazine/2000/1/cover2), used approximately 1–1.5 g of extract once daily for two weeks in men complaining of low desire or erectile difficulty, the shortest schedule reported to produce a response.

* **Competing approach — multi-herb formulas:** Brazilian practice favours Catuama, a fixed combination of muira puama, guarana, catuaba and ginger developed by Laboratório Catarinense, [dosed as capsules or as 25 mL of liquid twice daily](https://pubmed.ncbi.nlm.nih.gov/15798997/).

* **Competing approach — nitric-oxide combinations:** A United States group led by Jacob Rajfer developed COMP-4 or Revactin, delivering 125 mg each of muira puama, ginger and guarana with 400 mg L-Citrulline, two capsules twice daily.

* **Preparation matters:** The active constituents are fat-soluble, so water infusions extract them poorly. Alcohol-based tinctures and hydroalcoholic dry extracts are the forms used in every reported study.

* **Best time of day:** Morning or early afternoon, given the stimulant profile. For episodic sexual use, roughly 60–90 minutes before activity is the common practice, though no timing study supports it.

* **Half-life:** Unknown. No human pharmacokinetic study of muira puama or its constituents exists, so no elimination half-life, time to steady state, or dosing interval can be derived from data.

* **Single versus split dosing:** Both patterns are in use — Waynberg dosed once daily, the nitric-oxide formulas dose twice daily. Splitting is the more conservative default while tolerability is being established.

* **Genetic polymorphisms:** No pharmacogenetic guidance exists. BCHE variants, APOE4 status and CYP3A4 activity are all theoretically relevant to a cholinergic botanical, but no variant has been tested against response or dose.

* **Sex-based differences:** No sex-specific dose has been established. [The single study in women](https://pubmed.ncbi.nlm.nih.gov/11186145/) used the same extract dose alongside *Ginkgo biloba*, and reported comparable tolerability without any dosing adjustment.

* **Age-related considerations:** Older adults, especially those on several medications, are reasonably started at the lower end (500–1,000 mg) given greater sensitivity to cholinergic and blood-pressure effects and no trial data above age 39 for the vascular use.

* **Baseline biomarkers:** Checking testosterone, estradiol and a fasting metabolic panel first distinguishes a correctable hormonal or metabolic cause of low desire from one where a mild botanical is the appropriate next step.

* **Pre-existing conditions:** Response expectations should be set by the underlying cause — established vascular disease, diabetic neuropathy or clinical depression each demand their own treatment rather than an herb reported to help mild, largely functional complaints.

  
## Discontinuation & Cycling

* **Not a lifelong intervention:** Nothing in the evidence supports indefinite use. Every reported human schedule ran two weeks to three months, and no study has followed anyone beyond three months of continuous intake.

* **Withdrawal effects:** None documented. No dependence, rebound or discontinuation syndrome has been reported in any human study or case report, consistent with the absence of any known receptor-level dependence mechanism.

* **Tapering:** Not applicable. Given no withdrawal signal and the short schedules studied, abrupt discontinuation is the norm; there is no tapering protocol in any published source.

* **Cycling:** Commonly practised as roughly eight weeks on and two to four weeks off, on the assumption that tolerance develops. No study has tested tolerance, so the rationale is precautionary rather than evidence-based.

* **Stopping rule:** If no change in desire, erection quality, fatigue or sleep is detectable after 8–12 weeks at a full dose, continuing accumulates unquantified long-term exposure for no measured return.

  
## Sourcing and Quality

* **Species verification:** Products should name *Ptychopetalum olacoides* or *Ptychopetalum uncinatum* explicitly. Historic trade material was also sold as *Liriosma ovata*, and unlabelled botanical substitution is a documented problem across Amazonian herbs.

* **Plant part:** Root and root bark are the parts used in every study; stem wood is cheaper and weaker. A label reading simply "muira puama wood" is a warning sign about which part was actually harvested.

* **Extract ratio and solvent:** A stated ratio (typically 4:1) and hydroalcoholic extraction matter, because the fat-soluble actives do not transfer into water. An unspecified "extract" gives no basis for dose comparison.

* **Third-party testing for hidden drugs:** Certification through NSF Certified for Sport, USP Verified or Informed Choice matters more here than for most herbs, because this product category leads all others in concealed pharmaceutical adulteration.

* **Proprietary blends:** Multi-ingredient "male performance" formulas hide both the muira puama dose and the adulteration risk. Single-ingredient products or the specific combinations studied in trials are the only ones with a known composition.

* **Reputable options:** Herb Pharm and Nature's Answer market single-herb muira puama extracts with published testing programmes; the Revactin and Catuama formulations are the only branded combinations that have been used in registered human studies.

* **Sustainability:** The plant is wild-harvested from Amazonian forest and is not widely cultivated, so harvesting pressure is a genuine supply concern [noted in botanical references](https://grokipedia.com/page/Ptychopetalum) and a reason to prefer suppliers documenting their sourcing.

  
## Practical Considerations

* **Time to effect:** Waynberg's uncontrolled series, [per a supplement retailer's magazine](https://www.lifeextension.com/magazine/2000/1/cover2), reported changes within two weeks, and [the vascular trial](https://clinicaltrials.gov/study/NCT05595915) dosed for fourteen days. A realistic assessment window is 8–12 weeks, since nothing supports an immediate, dose-by-dose effect.

* **Common pitfall — expecting drug-like acute action:** Muira puama does not inhibit phosphodiesterase-5 and produces no on-demand erection. People who take it an hour before activity expecting a pharmaceutical effect will conclude, correctly, that nothing happened.

* **Common pitfall — brewing it as tea:** Because the actives are fat-soluble, a water decoction of root chips extracts very little. Most disappointing experiences with traditional preparations trace to the wrong solvent rather than the wrong plant.

* **Common pitfall — buying blends:** Purchasing a proprietary sexual-enhancement blend makes the muira puama dose unknowable and carries the documented adulteration risk that dominates this product category's safety record.

* **Regulatory status:** In the United States it is an unapproved dietary supplement ingredient with no approved therapeutic claim. Brazil's health regulator permits registered herbal-medicine combinations such as Catuama; the European Union approves no medicinal use.

* **Cost and payer incentives:** Roughly USD 10–25 per month, entirely out of pocket. Generic sildenafil is also inexpensive, and insurers commonly exclude erectile-dysfunction treatment altogether, so no institutional payer has a financial incentive favouring either option.

  
## Interaction with Foundational Habits

* **Sleep:** Blunting, by direction. The stimulant profile and the anxiety-provoking rodent signal both point toward delayed sleep onset at higher intakes. Practical consequence: the full dose belongs before 14:00, and new early-morning waking or restlessness is a dose-reduction signal rather than an unrelated event.

* **Nutrition:** Potentiating, through absorption. The active constituents are fat-soluble, so taking capsules with a meal containing fat plausibly improves uptake, exactly as the alcohol extraction step does. Practical consequence: dosing with breakfast rather than fasted, with tincture ethanol counted toward the day's alcohol intake.

* **Exercise:** No established interaction in either direction. [A review of herbals and human exercise performance](https://pubmed.ncbi.nlm.nih.gov/10919969/) found no controlled evidence that muira puama improves endurance, strength or recovery, and no evidence it blunts training adaptation. Practical consequence: no timing adjustment around workouts is warranted by data.

* **Stress management:** Potentiating under chronic stress and blunting without it, through adrenaline- and dopamine-type signalling. Rodent work shows it prevents stress-induced anxiety and blood-sugar rises in chronically stressed animals, yet is anxiety-provoking in unstressed ones at the same doses. Practical consequence: pairing with breathing or sleep work, and discontinuation if subjective tension rises.

  
## Monitoring Protocol & Defining Success

Baseline testing serves a specific purpose here: it separates a correctable cause of low desire, fatigue or poor erection quality from the mild, largely unproven effect this herb offers. Before starting, a reasonable panel covers total and free testosterone, sex hormone-binding globulin, a sensitive estradiol assay, a liver panel and a resting blood-pressure reading, alongside a written baseline score on the International Index of Erectile Function (a validated sexual-function questionnaire). Because the herb is uncharacterised metabolically, the liver panel is a safety anchor rather than an efficacy measure. Ongoing monitoring is light: recheck blood pressure and symptoms at two weeks, repeat the full panel and the questionnaire at eight weeks to decide whether to continue, and then every 6–12 months for anyone who stays on it long term.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Total testosterone | 600–900 ng/dL (men) | Shows whether low desire is hormonal rather than herb-responsive | Conventional reference range is far wider at 264–916 ng/dL; draw fasting before 10:00 and repeat any abnormal value |
| Free testosterone | 15–25 ng/dL (men) | The fraction actually available to tissue receptors | Best paired with SHBG (sex hormone-binding globulin, the carrier protein that ties up testosterone); calculated or equilibrium-dialysis methods differ |
| Estradiol, sensitive assay | 20–30 pg/mL (men) | Baseline for the herb's predicted estrogen-receptor activity | Order the mass-spectrometry "sensitive" assay; standard immunoassays are unreliable at male concentrations |
| SHBG | 20–40 nmol/L | High values lock up testosterone and mimic deficiency | Rises with age and alcohol intake; interpret only alongside free testosterone, not on its own |
| ALT | 10–26 U/L | Catches liver strain from a metabolically uncharacterised botanical | ALT is alanine aminotransferase, a liver enzyme; the conventional upper limit near 44 U/L is much looser than the functional target |
| hs-CRP | Below 1.0 mg/L | Tracks the inflammatory background the antioxidant claim targets | hs-CRP is high-sensitivity C-reactive protein; postpone testing until two weeks after any infection or injury |
| Resting blood pressure | Below 120/80 mmHg | Both the nitric-oxide claim and the adulteration hazard act here | Measure seated after five minutes' rest, plus a standing reading; recheck two weeks after starting |

Qualitative markers matter more than laboratory values for this intervention, because none of the claimed benefits has a validated blood marker:

* Frequency and intensity of sexual desire, tracked weekly rather than recalled
* Erection quality and reliability, scored on the International Index of Erectile Function at baseline and week eight
* Daytime fatigue and physical stamina
* Sleep onset latency and night-time waking, which are the earliest signals of overstimulation
* Subjective tension, restlessness or irritability
* Cognitive clarity and word-finding, given the cholinergic mechanism

  
## Emerging Research

* **Completed artery-function trial:** [NCT05595915](https://clinicaltrials.gov/study/NCT05595915) tested COMP-4, containing muira puama, in 32 healthy adults for fourteen days, measuring flow-mediated dilation (an ultrasound test of artery flexibility) and senescence markers. Completed November 2025; results not yet published.

* **Six-week extension trial:** [NCT07469475](https://clinicaltrials.gov/study/NCT07469475) is an open-label study in 35 participants asking whether the same supplement continues to suppress plasminogen activator inhibitor-1 over six weeks and affects other ageing-related blood markers.

* **Endothelial mechanism work:** [Ferrini et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39913351/) reported that the four-ingredient formula protects human endothelial cells through the nitric oxide pathway, the cell-level basis the two registered trials are testing in people.

* **Bone and fracture repair:** [Rajfer et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31275540/) found the same formula prevented bone loss in rats with ovaries removed. Whether this translates to human bone density is entirely untested and would be the natural next step.

* **Standardisation chemistry:** [Tian et al., 2018](https://pubmed.ncbi.nlm.nih.gov/28750557/) quantified magnoflorine and menisperine as the dominant constituents, giving the first practical basis for standardising extracts — a precondition for any credible future trial.

* **Evidence that could weaken the case:** [Borrelli et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29633089/) reviewed 24 randomized trials of herbal supplements for erectile dysfunction and found no muira puama trial eligible for inclusion, which is the strongest available signal that the human evidence remains absent.

* **Market-scoring analysis:** [Petre et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37686709/) scored marketed erectile-dysfunction supplements and judged 80% to have no expected efficacy, a framework that could be applied directly to muira puama products once a defensible effective dose exists.

  
## Conclusion

Muira puama is an Amazonian root and bark preparation with a long, two-sided reputation — a sexual tonic and a remedy for nervous exhaustion — and a modern laboratory profile that touches both brain chemistry and blood-vessel relaxation. The gap between that profile and the human evidence is wide. The sexual-function claim rests on small studies from a single investigator that had no comparison group and were reported mainly through supplement-industry channels, and on similar studies of formulas in which the herb is one ingredient among several. Its memory, mood, stress and bone findings are all animal-level. Nothing has been tested against placebo on its own.

That is a statement about missing evidence rather than about failure: no trial has tested and refuted the claim either. Side effects in the human studies that do exist have been mild, with stomach upset and headache the main reports, and restlessness or disturbed sleep the main caution at higher intakes. The largest practical hazard is not the plant but the product category it sits in, where concealed prescription drugs are common enough to be the dominant safety concern.

Much of the favourable literature comes from parties selling the herb or the formulas containing it, and that commercial link is itself a feature of the evidence base. For someone weighing a low-cost, mild intervention whose upside is unproven, the honest summary is a believable mechanism, a thin record, and a product market in which hidden drugs are common.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**